Pancreatic Cancer Research

ResearcherWuhan Union HospitalActive in the last 2 years

Taoyu Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8966-1264; OpenAlex author ID A5054171297. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2022: 3 papers · 2023: 1 paper · 2024: 3 papers · 2025: none · 2026: 3 papers

Papers 10

  1. HDAC5 depletion promotes hyper-acetylation of FOXA1 and potentiates HIF1α transcriptional activation in pancreatic cancer. Co-author DOI 10.1016/j.molcel.2026.06.022↗
  2. PRMT1-Mediated Arginine Methylation Redirects SMAD4 Signaling to Promote Metastasis in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-0923↗
  3. HDAC1 Regulates Acquired Resistance to EGFR Inhibitors through the TFCP2-NDRG1 Signaling Axis in Pancreatic Cancer. Co-author DOI 10.7150/ijbs.131003↗
  4. Pancreatic cancer stem cell-derived exosomal miR-210 mediates macrophage M2 polarization and promotes gemcitabine resistance by targeting FGFRL1. Co-author DOI 10.1016/j.intimp.2023.111407↗
  5. BAP1 regulates HSF1 activity and cancer immunity in pancreatic cancer. Co-author DOI 10.1186/s13046-024-03196-4↗
  6. Single-cell and spatial transcriptomic analyses reveal the cellular origins and drivers of liver metastasis from pancreatic cancer Co-author DOI 10.21203/rs.3.rs-4128922/v1↗
  7. MST2 methylation by PRMT5 inhibits Hippo signaling and promotes pancreatic cancer progression. Co-author DOI 10.15252/embj.2023114558↗
  8. A nomogram predicting overall survival for metastatic pancreatic cancer: SEER database analysis Co-author DOI 10.21203/rs.3.rs-1410601/v1↗
  9. Tumor Cell Derived Exosomal GOT1 Suppresses Tumor Cell Ferroptosis to Accelerate Pancreatic Cancer Progression by Activating Nrf2/HO-1 Axis via Upregulating CC… First author DOI 10.3390/cells11233893↗
  10. HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer. Co-author DOI 10.7150/thno.69444↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Heshui Wu · 5 shared papers, 2022–2026 · strength 0.98
  2. Dianyun Ren · 3 shared papers, 2022–2026 · strength 0.66
  3. Shanmiao Gou · 3 shared papers, 2022–2026 · strength 0.66
  4. Tao Yin · 3 shared papers, 2022–2026 · strength 0.63
  5. Yingke Zhou · 3 shared papers, 2022–2026 · strength 0.62
  6. Gengdu Qin · 3 shared papers, 2022–2026 · strength 0.62
  7. Yao Guo · 2 shared papers, 2024 · strength 0.47
  8. Tao Peng · 2 shared papers, 2022–2024 · strength 0.38
  9. Haixin Yu · 2 shared papers, 2022–2026 · strength 0.37
  10. Jingyuan Zhao · 2 shared papers, 2022–2024 · strength 0.35
  11. Xin Jin · 2 shared papers, 2022–2023 · strength 0.33
  12. Tao Peng · 1 shared paper, 2024 · strength 0.26
  13. Yizhou Liu · 1 shared paper, 2026 · strength 0.26
  14. Hongkun Cai · 1 shared paper, 2026 · strength 0.26
  15. Jing Cui · 1 shared paper, 2024 · strength 0.21
  16. Yuhan Zhao · 1 shared paper, 2024 · strength 0.20
  17. Weiwei Yuan · 1 shared paper, 2024 · strength 0.20
  18. Jinxi Huang · 1 shared paper, 2024 · strength 0.20
  19. Junpeng Meng · 1 shared paper, 2023 · strength 0.19
  20. Feng Guo · 1 shared paper, 2023 · strength 0.19
  21. Yan Sun · 1 shared paper, 2023 · strength 0.19
  22. Jing Cui · 1 shared paper, 2022 · strength 0.17
  23. Yao Guo · 1 shared paper, 2022 · strength 0.17
  24. Jiaoshun Chen · 1 shared paper, 2022 · strength 0.16
  25. Kun Liu · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.